Burning Rock Biotech (BNR) Stock: Buy, Sell, or Hold?
BNR - Burning Rock Biotech Limited American Depositary Shares
$13.25
0.42 (3.27%)
▲
5d:
+19.91%
30d:
-12.71%
90d:
+50.4%
BUY
HIGH Confidence
Analysis Updated: Nov 5, 2026 12:00 AM ET
Earnings: Nov 19, 2026
12d
Get Alerted When BNR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: BNR shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
✅ BUY SIGNAL: BNR shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
In-depth Analysis How we analyze
Valuation Analysis: BNR is currently trading at $13.25, which is considered fair relative to its 30-day fair value range of $11.70 to $16.25.
Technical Outlook: Technically, BNR is in a uptrend. The price is approaching resistance at $13.51. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.3% recently.
Market Sentiment: BNR scores 86/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. However, the stock is trading significantly above the average Wall Street target of $4.03. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, BNR is in a uptrend. The price is approaching resistance at $13.51. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.3% recently.
Market Sentiment: BNR scores 86/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. However, the stock is trading significantly above the average Wall Street target of $4.03. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$11.70 -
$16.25
Company Quality Score
66/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
81.6%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Strong technical setup (86/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.3%)
- BEARISH: Trading 69.6% above Wall St target ($4.03)
- BULLISH: Bottoming setup score 86/100 — corrected, stabilizing, and turning up
Trading Range Analysis
30-Day Trading Range
$11.70 -
$16.25
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$9.98
Resistance Level
$13.51
Current Trend
Uptrend
Technical data as of
Nov 5, 2026
Fundamental Context
Wall Street Target
$4.03
(-69.6%)
Revenue Growth (YoY)
-9.3%
Profit Margin
-13.6%
Share & Embed Analysis
Last updated: November 06, 2026 6:04 AM ET
Data refreshes hourly during market hours. Next update: 7:04 AM
Data refreshes hourly during market hours. Next update: 7:04 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BNR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Diagnostics & Research Stocks
Top-rated stocks in Diagnostics & Research by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
GH
Guardant Health Inc |
STRONG BUY
26 analysts |
$202 | 53 HOLD |
|
EXAS
EXACT Sciences Corporati… |
STRONG BUY
26 analysts |
$106 | 52 HOLD |
|
TMO
Thermo Fisher Scientific… |
STRONG BUY
27 analysts |
$752 | 45 HOLD |
|
NTRA
Natera Inc |
STRONG BUY
23 analysts |
$416 | 51 HOLD |
|
DHR
Danaher Corporation |
STRONG BUY
24 analysts |
$260 | 47 HOLD |
